Abstract Number: 1959 • ACR Convergence 2023
Quantitative Scoring of High Resolution Chest Computed Tomography (HRCT) Images in Myositis and Antisynthetase Syndrome Related Interstitial Lung Disease in Comparison to Scleroderma Related Interstitial Lung Disease
Background/Purpose: High resolution computed tomography (HRCT) of the chest has become an important modality in the evaluation of interstitial lung disease (ILD). A quantitative CT…Abstract Number: 2514 • ACR Convergence 2023
Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis
Background/Purpose: Myositis is an infrequent but serious complication associated with immune check point inhibitor (ICI) treatment. Many patients with ICI-induced myositis will develop concurrent myocarditis…Abstract Number: 0150 • ACR Convergence 2023
Self-reported Levels of Physical Activity and the Association to Pain, Fatigue, Anxiety and Depression Among Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Patients with inflammatory diseases such as rheumatoid arthritis exhibit reduced levels of physical activity (PA) compared to the normative population and suffer from anxiety…Abstract Number: 0303 • ACR Convergence 2023
Development of a Human Cytotoxic Myoinjury Model with CD8+ T Cells and Muscle Cells Differentiated from Human Induced Pluripotent Stem Cells
Background/Purpose: CD8+ cytotoxic lymphocytes (CTLs) play a crucial role in the myoinjury of polymyositis (PM). Nonetheless, conventional treatment for PM depends on high-dose glucocorticoids with…Abstract Number: 1160 • ACR Convergence 2023
Antibody Predictors of Prognosis in a Large Multi-centre Cohort of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
Background/Purpose: IIM-ILD follows a varied clinical course. Serological profile can help predict clinical phenotype, but impact on ILD prognosis is less clear. This multicentre UK…Abstract Number: 1231 • ACR Convergence 2023
Successful Implementation of a Mental Health Screening Program for Youth with Juvenile Dermatomyositis
Background/Purpose: High levels of emotional distress have been reported in children with juvenile myositis (JM). Inadequate recognition of mental health concerns by healthcare providers (HCPs)…Abstract Number: 1960 • ACR Convergence 2023
From Clinical Amyopathy to Severe Oropharyngeal Dysphagia in Pure Dermatomyositis: A Greater Extent of Muscle Weakness Is Associated with a Higher Cancer Prevalence
Background/Purpose: The risk of cancer is increased in patients with pure dermatomyositis (DM), i.e. patients with a DM rash and without an anti-MDA-5 syndrome, a…Abstract Number: 2515 • ACR Convergence 2023
Machine Learning-Based Stratification of Mixed Connective Tissue Disease Using Immunophenotyping Data from Patients with Related Autoimmune Diseases
Background/Purpose: Mixed connective tissue disease (MCTD) is a heterogenous autoimmune disorder with overlapping clinical features of systemic lupus erythematosus (SLE), polymyositis/dermatomyositis, and systemic sclerosis (SSc).…Abstract Number: 0169 • ACR Convergence 2023
Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective
Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) is a subgroup of immune-mediated myopathies (IMM). The diagnosis of IMNM relied on the presence of proximal muscle weakness, high…Abstract Number: 0304 • ACR Convergence 2023
Incidence of Disease Flares Following COVID-19 Vaccination in a Diverse Idiopathic Inflammatory Myopathy Cohort
Background/Purpose: Autoimmune activation in the setting of vaccination against coronavirus disease 2019 (COVID-19) is a well-documented phenomenon in the medical literature. For patients with idiopathic…Abstract Number: 1161 • ACR Convergence 2023
Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models
Background/Purpose: Dermatomyositis (DM) is an autoimmune myopathy responsible for muscle weakness associated with decreased quality of life and increased mortality. DM muscular histology is characterized…Abstract Number: 1246 • ACR Convergence 2023
Assessment and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis
Background/Purpose: Calcinosis is a poorly understood and morbid complication of juvenile dermatomyositis (JDM). As there is no consensus treatment approach for calcinosis, and limited knowledge…Abstract Number: 1961 • ACR Convergence 2023
Anti-PM/Scl Autoantibodies in Juvenile Myositis Are Associated with a Distinct Phenotype Resembling Anti-synthetase Syndrome
Background/Purpose: Anti-PM/Scl autoantibodies (Abs) are an uncommon myositis-associated autoantibody (MAA) in juvenile myositis. The clinical features and outcomes associated with anti-PM/Scl Abs in juvenile myositis…Abstract Number: 2575 • ACR Convergence 2023
Accurate Stratification of Cancer Risk in a Real-World Cohort Using the International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening
Background/Purpose: Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increased cancer risk within three years prior to or following IIM onset. The International Guideline…Abstract Number: 0283 • ACR Convergence 2023
Transcriptomic Profiles in Muscle Biopsies from Systemic Sclerosis Patients with Different Autoantibodies
Background/Purpose: The inflammatory myopathies (IM) include dermatomyositis (DM), antisynthetase syndrome (AS), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), and overlap myositis (OM), in which…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 28
- Next Page »